- Conditions
- Angelman Syndrome
- Interventions
- OV101 Regimen 1, OV101 regimen 2, Placebo
- Drug · Other
- Lead sponsor
- Healx AI
- Industry
- Eligibility
- 13 Years to 49 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Diego, California • Gainesville, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Angelman Syndrome
- Interventions
- OV101
- Drug
- Lead sponsor
- Healx AI
- Industry
- Eligibility
- 13 Years to 49 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • San Diego, California • Atlanta, Georgia + 7 more
- Conditions
- Angelman Syndrome, Fragile X Syndrome
- Interventions
- OV101
- Drug
- Lead sponsor
- Ovid Therapeutics Inc.
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Nashville, Tennessee
- Conditions
- Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
- Interventions
- Gaboxadol, Placebo
- Drug
- Lead sponsor
- Ovid Therapeutics Inc.
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Chicago, Illinois + 6 more
- Conditions
- Fragile X Syndrome (FXS)
- Interventions
- OV101 (gaboxadol)
- Drug
- Lead sponsor
- Ovid Therapeutics Inc.
- Other
- Eligibility
- 13 Years to 22 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Sacramento, California • Aurora, Colorado • Chicago, Illinois + 3 more